Full history for every metric is available with a Kvantra account
Psyence Group Inc. (PSYG.CN)
Key financial summary
Financials in CAD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | CAD m | -6 | -2 | |||||
| Net profit | CAD m | -0 | -0 | -5 | -6 | -69 | -0 | - |
| EPS reported | CAD | -0.04 | - | |||||
| Operating cashflow per share | CAD | -0.59 | -0.18 | |||||
| Capex per share | CAD | 0.00 | 0.00 | |||||
| FCF per share | CAD | -0.60 | -0.18 | |||||
| Free cash flow | CAD m | -6 | -3 | |||||
| Net debt | CAD m | -9 | -1 | |||||
| Book value equity | CAD m | 1 | 1 | |||||
| Book value per share | CAD | 0.14 | 0.05 | |||||
| Number of shares | m | 9.34 | 14.65 | |||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.43 | 2.41 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.33 | -0.72 | |||||
| EV/EBITDA LTM | x | 1.28 | -0.11 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -21.67% | -742.06% | |||||
| FCF Yield | % | -301.20% | -139.70% | |||||
| Quality | ||||||||
| ROE | % | -31.09% | -1435.7% | |||||
| ROIC | % | -57.72% | -274.39% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 1.61 | 0.04 | |||||
| EBIT/Net interest | x | -429.32 | -70.12 | |||||
| Net debt/market cap | % | -481.26% | -26.11% | |||||
| Net debt/Equity | x | -6.91 | -0.63 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Psyence Group Inc. is a life sciences biotechnology company primarily engaged in the commercial cultivation and production of psilocybin mushrooms. This naturally sourced psilocybin is intended for therapeutic applications, addressing a broad spectrum of mental health conditions and other medical ailments. The company is actively formulating pharmaceutical-grade psilocybin treatments designed to mitigate psychological trauma and recognized disorders such as anxiety, depression, post-traumatic stress disorder (PTSD), and the emotional distress linked to grief and bereavement. Furthermore, Psyence Group develops, distributes, and sells over-the-counter functional mushroom nutraceuticals, entirely free of psilocybin, under its GOODMIND brand. Established in 2019, the company maintains its headquarters in Toronto, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Psyence Group Inc. (PSYG.CN)
Psyence Group Inc. is a life sciences biotechnology company primarily engaged in the commercial cultivation and production of psilocybin mushrooms. This naturally sourced psilocybin is intended for therapeutic applications, addressing a broad spectrum of mental health conditions and other medical ailments. The company is actively formulating pharmaceutical-grade psilocybin treatments designed to mitigate psychological trauma and recognized disorders such as anxiety, depression, post-traumatic stress disorder (PTSD), and the emotional distress linked to grief and bereavement. Furthermore, Psyence Group develops, distributes, and sells over-the-counter functional mushroom nutraceuticals, entirely free of psilocybin, under its GOODMIND brand. Established in 2019, the company maintains its headquarters in Toronto, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free